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Introduction
Recent studies have led to the discovery of certain potent non-steroidal contraceptives, some of which have been com¬ mercialized (for example, centchroman in the form of Saheli) (Puri et al, 1988) , while others are still being developed (Fasoli et al, 1989; Dhar et al, 1991; Mehrotra et al, 1991) . Among these, a number of triphenylethylene derivatives have potent anti-implantation activity, for example, clomiphene (Holtcamp et al, 1968) , nafoxidene (Lednicer el al, 1963) , tamoxifen (Harper and Walpole, 1967) and centchroman (Kamboj et al, 1977) . These non-steroidal anti-oestrogens have gained impor¬ tance because of their ability to antagonize the effect of oestrogen at a common site of action (Emmens et al, 1962; Durani et al, 1979) . Many of these well known antioestrogenic compounds, such as centchroman (Kamboj et al, 1977; Puri et al, 1988) and tamoxifen (Furr and Jordan, 1984;  Gill-Sharma et al, 1993; Poyser, 1993) , display weak oestro¬ genic activity. Kamboj et al. (1977) showed that centchroman has significant uterotropic activity and induces vaginal cornification in immature rats. The biological profile of tamoxifen is complex and displays both oestrogen antagonism and oestrogen agonism, depending upon its concentration, the sex of the animal and the target organ. In rats, tamoxifen is predominantally anti-oestrogenic with weak oestrogenic activ¬ ity (Furr and Jordan, 1984 (Poyser, 1993) . The present study elaborates on the contraceptive potential and the mode of action of a non-steroidal compound, 2-[piperdinoethoxyphenyl]-3-[4-methoxyphenyl]-2H benzopyran (K-7), which was synthesized in the laboratory of R. S. Kapil (Kapil et al, 1989) . The chemical structure of K-7 is shown (Fig. 1 
Results
Initial studies showed that compound K-7 prevents pregnancy in rats when given orally as a single dose or from day 1-10 of pregnancy (Table 1) and also when a single dose is given i.p. or These results have established that K-7 has weak oestrogenic and potent anti-oestrogenic activity in vivo and that it is effective in preventing conception when administered during the preimplantation period. This finding suggests that the compound interferes with some mechanisms in the uterus associated with the implantation of the blastocyst. Brandon (1980) reported that oestradiol initiates implantation in the adequately prepared endometrium in rats. Oestrogen availabil¬ ity is required from the evening of day 4 of pregnancy to induce the receptive phase, which appears at about 12:00 h on day 5 (Psychoyos, 1973 Prapas, 1987) . In rats, this oestrogenic activity, when given early in pregnancy, stimulates egg transport and results in the prevention of implantation (Psychoyos, 1973; Finn, 1977 (Durani et al, 1979; Jordan and Gosden, 1982) . Compound K-7 resembles other non-steroidal anti-oestrogens structurally in possessing a basic amino-ether side chain (Jordan and Gosden, 1982 (Holtcamp et al, 1968; Katzenellenbogen et al, 1975; Jordan et al, 1977; Dhar et al, 1991; Mehrotra et al, 1991; Sreenivasulu et al, 1992) . Although tamoxifen has an affinity of about 1.67% of oestradiol, its major nonconjugated metabolite, monohydroxy-tamoxifen, has an affinity equivalent to that of oestradiol (Jordan et al, 1977) . The receptor binding of the hydroxy-derivative of centchroman was found to be higher and the phenolic analogue is as potent as oestradiol (Durani and Anand, 1981; Sreenivasulu et al, 1992) . This study was financially supported by CSIR India. The author thanks R. S. Kapil, Director, R.R.L., Jammu, J&K, India for providing the compound K-7, and R. Nandini and V. Vijaylakshami for review¬ ing the manuscript.
